VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
INVAInnoviva, Inc.
$22.49$1.7B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

INVA logoInnoviva, Inc.(INVA)Earnings, Financials & Key Ratios

INVA•NASDAQ
6.8× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryRoyalty and IP Monetization Vehicles
AboutInnoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Show more
  • Revenue$425M+18.5%
  • EBITDA$204M+5.8%
  • Net Income$271M+1059.2%
  • EPS (Diluted)3.30+816.7%
  • Gross Margin72.33%-19.4%
  • EBITDA Margin47.98%-10.7%
  • Operating Margin38.52%-17.2%
  • Net Margin63.78%+878.1%
  • ROE29.09%+749.6%

INVA Key Insights

Innoviva, Inc. (INVA) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Excellent 3Y average ROE of 20.5%
  • ✓FCF machine: 46.1% free cash flow margin
  • ✓Healthy 5Y average net margin of 52.1%

✗Weaknesses

  • ✗Shares diluted 14.3% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when INVA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

INVA Price & Volume

Innoviva, Inc. (INVA) stock price & volume — 10-year historical chart

Loading chart...

INVA Growth Metrics

Innoviva, Inc. (INVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years22.93%
5 Years4.77%
3 Years8.66%
TTM13.61%

Profit CAGR

10 Years-
5 Years3.86%
3 Years8.22%
TTM944.46%

EPS CAGR

10 Years-
5 Years10.31%
3 Years11.67%
TTM683.1%

Return on Capital

10 Years30.91%
5 Years19.33%
3 Years12.32%
Last Year12.36%

INVA Recent Earnings

Innoviva, Inc. (INVA) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.44+2.3%
$0.43
Rev
$98M-3.5%
$102M
Q1 2026
Feb 25, 2026
Metric
Actual
Est
EPS
$1.94+470.6%
$0.34
Rev
$115M+11.7%
$103M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$1.08+134.8%
$0.46
Rev
$108M+6.2%
$102M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$0.77+35.1%
$0.57
Rev
$100M+10.3%
$91M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.44vs $0.43+2.3%
$98Mvs $102M-3.5%
Q1 2026Feb 25, 2026
$1.94vs $0.34+470.6%
$115Mvs $103M+11.7%
Q4 2025Nov 5, 2025
$1.08vs $0.46+134.8%
$108Mvs $102M+6.2%
Q3 2025Aug 6, 2025
$0.77vs $0.57+35.1%
$100Mvs $91M+10.3%
Based on last 12 quarters of dataView full earnings history →

INVA Peer Comparison

Innoviva, Inc. (INVA) competitors in Royalty and IP Monetization Vehicles — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
PRGO logoPRGOPerrigo Company plcDirect Competitor1.42B10.25-1.00-2.75%-43.5%-50.65%1.35
GSK logoGSKGSK plcProduct Competitor101.9B50.676.864.11%19.19%31.48%1.11
AZN logoAZNAstraZeneca PLCProduct Competitor271.19B174.9326.758.63%17.19%22.24%0.61
TEVA logoTEVATeva Pharmaceutical Industries LimitedProduct Competitor36.66B31.4826.234.31%9.02%20.69%2.20
AMRN logoAMRNAmarin Corporation plcProduct Competitor333.42M16.03-8.91-6.55%-15.64%-7.34%0.03
INCY logoINCYIncyte CorporationProduct Competitor19.62B98.2215.3221.22%26.71%29.31%0.01
ABBV logoABBVAbbVie Inc.Supply Chain383.17B216.6391.418.57%6.91%62.15%
MRK logoMRKMerck & Co., Inc.Supply Chain281.25B113.8715.641.18%28.12%36.14%0.96

Compare INVA vs Peers

Innoviva, Inc. (INVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PRGO

Most directly comparable listed peer for INVA.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare INVA against a more recognizable public peer.

Peer Set

Compare Top 5

vs PRGO, GSK, AZN, TEVA

INVA Income Statement

Innoviva, Inc. (INVA) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
217.22M261M261.02M336.79M391.87M331.34M310.46M358.71M425.13M424.12M
Revenue Growth %
62.63%20.16%0%29.03%16.35%-15.45%-6.3%15.54%18.52%13.61%
Cost of Goods Sold
1.35M000013.79M42.64M36.6M117.61M100.96M
COGS % of Revenue
0.62%----4.16%13.73%10.2%27.67%-
Gross Profit
215.86M▲ 0%
261M▲ 20.9%
261.02M▲ 0.0%
336.79M▲ 29.0%
391.87M▲ 16.4%
317.55M▼ 19.0%
267.82M▼ 15.7%
322.11M▲ 20.3%
307.52M▼ 4.5%
323.16M▲ 0%
Gross Margin %
99.38%100%100%100%100%95.84%86.27%89.8%72.33%76.2%
Gross Profit Growth %
63.31%20.91%0%29.03%16.35%-18.97%-15.66%20.27%-4.53%-
Operating Expenses
32.26M22.75M14.66M15.67M16.76M110.55M153.94M155.25M143.77M260.19M
OpEx % of Revenue
14.85%8.72%5.62%4.65%4.28%33.36%49.58%43.28%33.82%-
Selling, General & Admin
32.26M17.05M14.66M13.88M16.19M63.54M98.23M115.69M113.17M118.33M
SG&A % of Revenue
14.85%6.53%5.62%4.12%4.13%19.18%31.64%32.25%26.62%-
Research & Development
1.35M001.79M576K41.43M33.92M13.65M30.6M31.45M
R&D % of Revenue
0.62%--0.53%0.15%12.5%10.93%3.81%7.2%-
Other Operating Expenses
-1.35M5.7M0005.58M21.78M25.9M02M
Operating Income
183.6M▲ 0%
238.25M▲ 29.8%
246.36M▲ 3.4%
321.12M▲ 30.3%
375.1M▲ 16.8%
207M▼ 44.8%
113.89M▼ 45.0%
166.87M▲ 46.5%
163.75M▼ 1.9%
62.97M▲ 0%
Operating Margin %
84.53%91.28%94.38%95.35%95.72%62.47%36.68%46.52%38.52%14.85%
Operating Income Growth %
68.46%29.76%3.4%30.35%16.81%-44.82%-44.98%46.52%-1.87%-
EBITDA
197.59M252.12M260.23M372.58M464.35M212.58M135.67M192.77M203.97M86.29M
EBITDA Margin %
90.96%96.6%99.7%110.62%118.5%64.16%43.7%53.74%47.98%20.35%
EBITDA Growth %
60.71%27.6%3.22%43.17%24.63%-54.22%-36.18%42.09%5.81%-36.34%
D&A (Non-Cash Add-back)
13.98M13.87M13.87M005.58M21.78M25.9M40.23M23.32M
EBIT
183.6M234.21M246.36M372.58M464.35M302.74M213.25M59.6M343.56M415.59M
Net Interest Income
-42.29M-22.29M-13.12M-16.81M-17.23M-9.42M-3.34M-3.07M4.39M4.53M
Interest Income
1.31M1.66M5.54M1.52M1.84M6.37M15.82M19.14M21.09M11.08M
Interest Expense
43.6M23.95M18.66M18.33M19.07M15.79M19.16M22.21M16.7M6.55M
Other Income/Expense
-49.33M-28M-13.46M33.12M70.17M79.95M80.21M-129.48M163.12M537.04M
Pretax Income
134.27M▲ 0%
210.25M▲ 56.6%
232.9M▲ 10.8%
354.25M▲ 52.1%
445.28M▲ 25.7%
286.95M▼ 35.6%
194.1M▼ 32.4%
37.39M▼ 80.7%
326.86M▲ 774.2%
600.01M▲ 0%
Pretax Margin %
61.81%80.56%89.23%105.18%113.63%86.6%62.52%10.42%76.89%141.47%
Income Tax
4K-196.07M41.9M60.43M76.44M66.69M14.38M14M55.7M-266K
Effective Tax Rate %
0%-93.25%17.99%17.06%17.17%23.24%7.41%37.43%17.04%-0.04%
Net Income
134.14M▲ 0%
395.06M▲ 194.5%
157.29M▼ 60.2%
224.4M▲ 42.7%
265.85M▲ 18.5%
213.92M▼ 19.5%
179.72M▼ 16.0%
23.39M▼ 87.0%
271.17M▲ 1059.2%
504.34M▲ 0%
Net Margin %
61.76%151.36%60.26%66.63%67.84%64.56%57.89%6.52%63.78%118.91%
Net Income Growth %
125.31%194.5%-60.19%42.67%18.47%-19.53%-15.99%-86.98%1059.22%944.46%
Net Income (Continuing)
134.27M406.33M190.99M293.81M368.84M220.26M179.72M23.39M271.17M504.34M
Discontinued Operations
0000000000
Minority Interest
152K5.47M28.62M67.92M111.19M00000
EPS (Diluted)
1.17▲ 0%
3.53▲ 201.7%
1.43▼ 59.5%
2.02▲ 41.3%
2.87▲ 42.1%
2.37▼ 17.4%
2.20▼ 7.2%
0.36▼ 83.6%
3.30▲ 816.7%
5.94▲ 0%
EPS Growth %
120.75%201.71%-59.49%41.26%42.08%-17.42%-7.17%-83.64%816.67%683.1%
EPS (Basic)
1.253.921.562.213.243.072.920.374.02-
Diluted Shares Outstanding
119.87M113.41M113.41M113.55M94.31M95.25M86.88M74.19M84.76M84.85M
Basic Shares Outstanding
106.94M100.85M101.15M101.32M82.06M69.64M65.44M62.73M67.39M74.16M
Dividend Payout Ratio
0.21%0.02%0.01%-------

INVA Balance Sheet

Innoviva, Inc. (INVA) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
199.62M199.04M431.23M342.06M313.67M443.51M344.22M554.31M727.51M772.62M
Cash & Short-Term Investments
129.07M114.91M350.85M246.49M201.53M291.05M193.51M412.5M550.94M611.93M
Cash Only
73.34M62.42M278.1M246.49M201.53M291.05M193.51M304.96M550.94M603.09M
Short-Term Investments
55.74M52.49M72.75M0000107.53M08.85M
Accounts Receivable
70.54M83.29M79.43M93.93M110.71M64.07M84.08M86.37M34.97M92.63M
Days Sales Outstanding
118.53116.47111.07101.8103.1270.5898.8487.8830.0266.56
Inventory
-754K000055.9M40.74M33.73M39.17M38.84M
Days Inventory Outstanding
-----1.48K348.71336.35121.57149.47
Other Current Assets
000070K2.93M4.26M656K102.44M4.38M
Total Non-Current Assets
167.72M349.15M293.59M657.51M612.72M787.99M899.29M746.75M907.65M1.06B
Property, Plant & Equipment
209K160K33K28K109K3.44M3.02M2.97M12.48M12.79M
Fixed Asset Turnover
1039.32x1631.28x7909.58x12028.36x3595.10x96.46x102.84x120.90x34.05x55.77x
Goodwill
0000026.71M17.91M17.91M17.91M17.91M
Intangible Assets
00000252.92M230.34M208.43M182.16M175.6M
Long-Term Investments
000438.26M483.85M403.01M560.98M393.96M193.73M1.73B
Other Non-Current Assets
167.51M152.94M139.39M125.47M128.77M101.91M87.05M111.44M501.38M93.21M
Total Assets
367.34M▲ 0%
548.19M▲ 49.2%
724.83M▲ 32.2%
999.57M▲ 37.9%
926.39M▼ 7.3%
1.23B▲ 32.9%
1.24B▲ 1.0%
1.3B▲ 4.6%
1.64B▲ 25.7%
1.84B▲ 0%
Asset Turnover
0.59x0.48x0.36x0.34x0.42x0.27x0.25x0.28x0.26x0.27x
Asset Growth %
-3.08%49.23%32.22%37.9%-7.32%32.93%0.98%4.63%25.68%97%
Total Current Liabilities
34.74M5.7M5.37M6.11M5.81M134.97M38.13M236.08M49.7M36.56M
Accounts Payable
601K11K10K66K27K2.94M6.72M2.13M4.97M6.52M
Days Payables Outstanding
161.89----77.7757.521.2615.4120.89
Short-Term Debt
25M000096.19M0192.03M418K5.34M
Deferred Revenue (Current)
-19.68M00002.09M1.28M1.13M4.27M11.07M
Other Current Liabilities
19.68M5.22M4.71M002.64M06.44M40.04M16.69M
Current Ratio
5.75x34.92x80.29x55.98x54.02x3.29x9.03x2.35x14.64x21.13x
Quick Ratio
5.77x34.92x80.29x55.98x54.02x2.87x7.96x2.21x13.85x20.07x
Cash Conversion Cycle
-----1.47K390.06402.96136.18195.14
Total Non-Current Liabilities
575.3M383.44M377.34M385.62M394.65M530.74M530.42M373.82M412.63M458.37M
Long-Term Debt
574.36M382.86M377.12M385.52M394.65M444.18M446.23M256.32M257.73M315.39M
Capital Lease Obligations
000002.38M1.64M1.18M10.87M23.46M
Deferred Tax Liabilities
000005.77M563K031.79M104.62M
Other Non-Current Liabilities
940K586K219K106K078.41M81.99M116.32M112.24M59.46M
Total Liabilities
610.04M389.14M382.71M391.73M400.46M665.71M568.55M609.9M462.32M494.93M
Total Debt
599.36M382.86M377.12M385.52M394.76M544.07M449.08M451.1M269.02M331.42M
Net Debt
526.03M320.44M99.02M139.03M193.23M253.02M255.56M146.13M-281.92M-271.67M
Debt / Equity
-2.41x1.10x0.63x0.75x0.96x0.67x0.65x0.23x0.25x
Debt / EBITDA
3.03x1.52x1.45x1.03x0.85x2.56x3.31x2.34x1.32x3.84x
Net Debt / EBITDA
2.66x1.27x0.38x0.37x0.42x1.19x1.88x0.76x-1.38x-3.15x
Interest Coverage
4.21x9.78x13.20x20.32x24.35x19.17x11.13x2.68x20.57x63.45x
Total Equity
-242.71M▲ 0%
159.05M▲ 165.5%
342.12M▲ 115.1%
607.84M▲ 77.7%
525.93M▼ 13.5%
565.79M▲ 7.6%
674.96M▲ 19.3%
691.16M▲ 2.4%
1.17B▲ 69.7%
1.34B▲ 0%
Equity Growth %
31.24%165.53%115.1%77.67%-13.47%7.58%19.29%2.4%69.69%235.56%
Book Value per Share
-2.021.403.025.355.585.947.779.3213.8415.81
Total Shareholders' Equity
-242.86M153.58M313.5M539.91M414.74M565.79M674.96M691.16M1.17B1.34B
Common Stock
1.02M1.01M1.01M1.01M696K692K633K627K747K738K
Retained Earnings
-1.5B-1.1B-946.4M-722M-456.15M-204.91M-25.19M-1.8M269.37M455.96M
Treasury Stock
-3.26M000-393.83M-393.83M-393.83M000
Accumulated OCI
-18K-3K27K0000000
Minority Interest
152K5.47M28.62M67.92M111.19M00000

INVA Cash Flow Statement

Innoviva, Inc. (INVA) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
141.75M223.53M257.46M313.11M363.81M201.73M141.06M188.69M196.93M183.59M
Operating CF Margin %
65.26%85.64%98.64%92.97%92.84%60.88%45.44%52.6%46.32%-
Operating CF Growth %
132.43%57.7%15.18%21.62%16.19%-44.55%-30.07%33.76%4.37%-32.46%
Net Income
134.27M406.33M190.99M293.81M368.84M220.26M179.72M23.39M271.17M504.34M
Depreciation & Amortization
13.98M13.87M13.87M013.83M19.51M35.7M39.85M40.23M86.84M
Stock-Based Compensation
9.83M3.23M2.06M1.7M2.02M7.35M5.84M6.37M9.45M18.59M
Deferred Taxes
7.15M-196.05M41.88M60.42M76.43M25.01M4.4M-12.62M43.85M47.04M
Other Non-Cash Items
4.79M12.91M5.57M-28.5M-80.43M-77.27M-59.81M138.62M-143.6M-523.69M
Working Capital Changes
-28.28M-16.76M3.1M-14.32M-16.87M6.87M-24.79M-6.93M-24.16M-27.06M
Change in Receivables
-23.69M-12.75M3.86M-14.5M-16.78M9.79M-20M-2.29M-6.95M-15.38M
Change in Inventory
0-3.43M-664K00280K-12M-6.81M-12.92M-3.77M
Change in Payables
473K-590K-1K56K-39K92K3.78M-4.58M2.83M266K
Cash from Investing
-23.24M3.52M-18M-314.94M43.72M-56.63M-66.76M-63.79M40.5M112.18M
Capital Expenditures
00-12K-13K-1.3M-67K-411K-270K-1.13M-2.74M
CapEx % of Revenue
--0%0%0.33%0.02%0.13%0.08%0.27%0.65%
Acquisitions
0017.99M-102.86M-235.81M-33.2M00019.94M
Investments
----------
Other Investing
00-17.99M0-20.98M-56.63M0-3.9M-929K29.01M
Cash from Financing
-163.19M-237.97M-23.78M-29.79M-452.5M-55.57M-171.84M-13.45M8.55M-11.78M
Debt Issued (Net)
-63.74M-230M-13.75M0066.37M-96.2M0-25K-25K
Equity Issued (Net)
-99.63M-1.93M538K344K-393.04M-8.59M-75.64M-13.45M8.58M8.39M
Dividends Paid
-281K-80K-11K0000000
Share Repurchases
-99.63M-3.07M-89K-92K-394.21M-8.59M-75.81M-14.92M-4.67M-4.61M
Other Financing
459K-5.96M-10.55M-30.13M-59.46M-113.35M000-20.15M
Net Change in Cash
-44.68M▲ 0%
-10.92M▲ 75.6%
215.68M▲ 2075.3%
-31.61M▼ 114.7%
-44.96M▼ 42.2%
89.52M▲ 299.1%
-97.54M▼ 208.9%
111.45M▲ 214.3%
245.98M▲ 120.7%
284M▲ 0%
Free Cash Flow
141.75M▲ 0%
223.53M▲ 57.7%
257.45M▲ 15.2%
313.1M▲ 21.6%
362.51M▲ 15.8%
201.66M▼ 44.4%
140.65M▼ 30.3%
188.42M▲ 34.0%
195.8M▲ 3.9%
180.85M▲ 0%
FCF Margin %
65.26%85.64%98.63%92.96%92.51%60.86%45.3%52.53%46.06%42.64%
FCF Growth %
133.5%57.7%15.17%21.62%15.78%-44.37%-30.25%33.96%3.92%-7.72%
FCF per Share
1.181.972.272.763.842.121.622.542.312.13
FCF Conversion (FCF/Net Income)
1.06x0.57x1.64x1.40x1.37x0.94x0.78x8.07x0.73x0.36x
Interest Paid
0009.93M011.74M010.36M00
Taxes Paid
0000053.85M011.79M00

INVA Key Ratios

Innoviva, Inc. (INVA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-248.38%62.77%47.24%46.9%39.19%28.97%3.42%29.09%47.59%
Return on Invested Capital (ROIC)
52.12%46.85%40.14%40.55%38.38%20.19%9.77%14.16%14.21%5.27%
Gross Margin
99.38%100%100%100%100%95.84%86.27%89.8%72.33%76.2%
Net Margin
61.76%151.36%60.26%66.63%67.84%64.56%57.89%6.52%63.78%118.91%
Debt / Equity
-2.41x1.10x0.63x0.75x0.96x0.67x0.65x0.23x0.25x
Interest Coverage
4.21x9.78x13.20x20.32x24.35x19.17x11.13x2.68x20.57x63.45x
FCF Conversion
1.06x0.57x1.64x1.40x1.37x0.94x0.78x8.07x0.73x0.36x
Revenue Growth
62.63%20.16%0%29.03%16.35%-15.45%-6.3%15.54%18.52%13.61%
Related:INVA Dividend History·INVA Revenue History·INVA Price History·INVA P/E History·INVA Financial Ratios·INVA Institutional Holders

INVA SEC Filings & Documents

Innoviva, Inc. (INVA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

May 4, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

4
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

INVA Frequently Asked Questions

Innoviva, Inc. (INVA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Innoviva, Inc. (INVA) reported $424.1M in revenue for fiscal year 2025. This represents a 271773% increase from $0.2M in 2002.

Innoviva, Inc. (INVA) grew revenue by 18.5% over the past year. This is strong growth.

Yes, Innoviva, Inc. (INVA) is profitable, generating $504.3M in net income for fiscal year 2025 (63.8% net margin).

Dividend & Returns

Innoviva, Inc. (INVA) has a return on equity (ROE) of 29.1%. This is excellent, indicating efficient use of shareholder capital.

Innoviva, Inc. (INVA) generated $180.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in INVA back in 2002?

Total return calculator · dividends reinvested · 24+ years of data

See returns →

How much would $100/month in INVA be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →